Last reviewed · How we verify
GST-HG141 tablets
At a glance
| Generic name | GST-HG141 tablets |
|---|---|
| Sponsor | Fujian Cosunter Pharmaceutical Co. Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets (PHASE2)
- Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets (PHASE1)
- Study on the Tolerance and Pharmacokinetics of GST-HG141 Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GST-HG141 tablets CI brief — competitive landscape report
- GST-HG141 tablets updates RSS · CI watch RSS
- Fujian Cosunter Pharmaceutical Co. Ltd portfolio CI